Boston, MA, October 15, 2026 – RE•WORK, part of Corinium Global Intelligence, is bringing the AI in Healthcare & Pharma Summit back to Boston on November 17–18, 2026, at the Hilton Boston Park Plaza. Under the theme “From AI Pilots to Clinical Impact,” the two-day summit will bring together leaders from healthcare, pharmaceuticals, biotechnology and life sciences to explore how artificial intelligence can deliver measurable value across clinical and business operations.
As AI adoption accelerates, healthcare and pharmaceutical organizations face growing pressure to move beyond experimentation and demonstrate tangible outcomes. From integrating AI into clinical workflows to accelerating drug development and navigating
increasingly complex regulatory requirements, the conversation is shifting from what AI can achieve to how organizations can implement it responsibly and at scale.
The summit will address these challenges through practical case studies, expert-led discussions, interactive panels and cross-industry knowledge sharing, offering attendees insights into the strategies, technologies and partnerships driving successful AI adoption.
The 2026 programme will explore key industry priorities, including:
- Scaling AI Beyond Pilots: Overcoming barriers to enterprise-wide implementation and demonstrating measurable return on investment.
- AI in Clinical Research and Drug Development: Exploring agentic AI, digital twins and intelligent automation to accelerate discovery and clinical trials.
- Data Foundations and Interoperability: Building the infrastructure, governance and data strategies required for reliable AI deployment.
- Responsible AI and Regulatory Readiness: Addressing transparency, compliance, trust and evolving regulatory expectations.
- Transforming Healthcare Delivery: Applying AI to clinical workflows, operational efficiency and improved patient outcomes.
The 2026 speaker lineup features experts from organizations including Novartis, Pfizer, Takeda, Bristol Myers Squibb, Merck, Gilead Sciences, Novo Nordisk, Eli Lilly and Company, GE HealthCare, BD, Aetna and Labcorp.
Among the featured speakers are Manohar Boorlu, Associate Director, AI Lead at Novartis;
Saad Saeed, Senior Director and Technology Head, AI Acceleration, Commercial Analytics & Specialty BU at Pfizer; Anuvrat Chaturvedi, Senior Director, Data Science at Gilead Sciences; and Vanessa Kitova, Staff Data Scientist, AI/ML, Enterprise AI at GE HealthCare.
Designed to encourage collaboration across traditionally separate sectors, the summit provides a platform for healthcare providers, pharmaceutical companies, MedTech organizations, researchers and technology leaders to exchange experiences and identify practical approaches to shared challenges.
Alongside the main conference programme, the summit will also spotlight emerging start-ups developing innovative AI applications across healthcare and life sciences, creating opportunities to connect established industry leaders with the next generation of innovators.
With AI increasingly embedded in healthcare and pharmaceutical operations, the AI in Healthcare & Pharma Summit Boston 2026 aims to help organizations translate technological progress into meaningful, sustainable impact.
Event Details
Event: AI in Healthcare & Pharma Summit Boston 2026
Dates: November 17–18, 2026
Venue: Hilton Boston Park Plaza, Boston, Massachusetts
Website: https://boston-ai-healthcare.re-work.co/
About RE•WORK
RE•WORK brings together global leaders, researchers and innovators to explore advancements in artificial intelligence and its real-world applications. Through industry-focused conferences and networking opportunities, RE•WORK connects professionals driving AI innovation across healthcare, finance, technology and beyond.
Disclaimer: This is a sponsored press release, and is for informational purposes only. It does not reflect the views of CryptoTotem, nor is it intended to be used as legal, tax, investment, or financial advice. The author or the publication does not hold any responsibility, directly, or indirectly, for any damage or loss caused or alleged to be caused by or connected with the use of or reliance on any content, goods or services mentioned in this article. Readers should conduct their own research before taking any actions related to this company.